Item 1. Security and Issuer.
This statement on Schedule 13D (this “Schedule 13D”) relates to the shares of common stock, par value $0.001 (“Common
Stock”), of Quince Therapeutics, Inc., a Delaware corporation (the “Issuer”), whose principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California 94080.
Item 2. Identity and Background.
| (a) |
This Schedule 13D is being filed by David A. Lamond (the “Reporting Person”).
|
| (b) |
The principal business office of the Reporting Person is c/o Quince Therapeutics, Inc., 611 Gateway Boulevard,
Suite 273, South San Francisco, California 94080. |
| (c) |
The Reporting Person is a member of the Board of Directors (the “Board”) of the Issuer.
|
| (d) – (e) |
During the last five years, the Reporting Person has not been (i) convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors) and (ii) a party to a civil proceeding of a judicial of administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
| (f) |
The Reporting Person is a citizen of the United States. |
Item 3. Source and Amount of Funds or Other Consideration.
GRAT Distribution
On March 4, 2021,
Reporting Person acquired 1,534,720 shares of Common Stock via a distribution from a grantor retained annuity trust to the David A. Lamond Trust dated 2006, of which the Reporting Person is the trustee.
Open Market Purchase
On August 15,
2023, Reporting Person purchased 107,886 shares of Common Stock at a weighted average price per share of $1.32 for aggregate purchase price of approximately $142,409.
Item 4. Purpose of Transaction.
The Reporting Person intends to review his investment in the Common Stock on a regular basis and, as a result thereof, may, directly or through
one or more affiliates, at any time or from time to time determine, either alone or as part of a group, (i) to acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions, or otherwise,
(ii) to dispose of all or a portion of the securities of the Issuer beneficially owned by him in the open market, in privately negotiated transactions, or otherwise, or (iii) to take any other available course of action, which could
involve one or more of the types of transactions or have one or more of the results specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Act of 1934, as amended. Any such acquisition or disposition or
other transaction would be made in compliance with all applicable laws and regulations, and subject to the terms and conditions of any agreements between the Reporting Person and the Issuer.
Notwithstanding anything contained herein, the Reporting Person intends to review his investment in the Issuer and the Issuer’s
performance and market conditions periodically and to take such actions with respect to his investment as it deems appropriate considering the circumstances existing from time to time. Accordingly, the Reporting Person specifically reserves the
right to change his intention with respect to any or all such matters described above. In reaching any decision as to his course of action (as well as to the specific elements thereof), the Reporting Person currently expects that he would take into
consideration a variety of factors, including, but not limited to, the following: the Issuer’s business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Issuer;
changes in law and government regulations; general economic conditions; tax considerations; other investment opportunities available to the Reporting Person; and prevailing market conditions, including the market price of the securities of Issuer.
4